Biopharma Companies Gain Faster Intelligence Through Direct Access to Raw Data, Bypassing Traditional Analysts.

Biopharma companies are increasingly utilizing direct raw data platforms to access and analyze intelligence, a shift away from relying on traditional analysts and their methodologies. This trend allows for potentially faster and more accurate data-driven decision-making within the industry. DrugPatentWatch reports that biopharma companies are now able to bypass intermediaries and gain direct access to raw data. Previously, these companies relied on analysts who utilized what the company describes as “outdated data.” The use of direct raw data platforms intends to allow companies to obtain biopharma intelligence with greater speed. Additional information on this shift is available on the DrugPatentWatch website.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

Related posts:

Breathing Patterns Influence Visual Perception, Study Finds Alarm Raised Over Ultra-Processed Foods Dominating Baby and Toddler Market “Immune Fingerprints” Transform Diagnosis of Complex Diseases Experts Urge Inclusion of Pets in Disease Surveillance Amid Rising H5N1 Cases in Cats

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後